Niosomes encapsulation of methotrexate and doxorubicin increase drug delivery to tumour and tumoricidal activity.
Unlike non stealth liposomes, 800 nm doxorubicin niosomes possessing a triglycerol or 200nm doxorubicin niosomes possessing a muramic acid surface are not significantly taken up by RES. These triglycerolniosomes accumulate in the tumour.
This may prove advantageous for treatment of hepatic neoplasm. The encapsulation of these polymeric prodrugs within 200nm niosomes provides a depot system within the liver from which the free drug is gradually cleaved off and the liver level of drug is increased over a 24 hour period.
Activity of other anticancer drugs, such as Vincristine, Bleomycin are also improved with niosomes encapsulation.
Niosome Therapies The uptake of Niosomes by the liver and spleen, makes them ideal for targeting disease manifesting in these organs, i.e. Leismaniasis. A number of studies have shown that Niosomal formulations of sodium stibogluconate improves parasite suppression in acting peptide drugs as intramuscular administration.